NCT04665284 (SAFE-PAK) is a Phase 4 clinical trial of Empagliflozin in Type II Diabetes Mellitus, sponsored by Getz Pharma.

Who is sponsoring NCT04665284?

NCT04665284 is sponsored by Getz Pharma.

What drugs are being tested in NCT04665284?

Interventions in NCT04665284: Empagliflozin, Usual care group.

What condition does NCT04665284 study?

NCT04665284 studies Type II Diabetes Mellitus.

Is NCT04665284 still recruiting?

NCT04665284 is currently completed. Last updated 11 December 2020.

Last reviewed 2020-12-11 · How we verify

NCT04665284: SAFE-PAK

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safety And Efficacy Of Empagliflozin In Pakistani Muslim Population With Type Ii Diabetes Mellitus

Completed Phase 4 Last updated 11 December 2020

What this trial tests

Phase 4 trial testing Empagliflozin in Type II Diabetes Mellitus in 244 participants. Completed in 28 September 2020.

Timeline

1 June 2019

Primary endpoint
15 September 2020

28 September 2020

Quick facts

Lead sponsor	Getz Pharma
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	244
Start date	1 June 2019
Primary completion	15 September 2020
Estimated completion	28 September 2020
Sites	11 locations across Pakistan

Drugs / interventions tested

Empagliflozin (empagliflozin) — full drug profile →
Usual care group — full drug profile →

Conditions studied

Type II Diabetes Mellitus — all drugs for Type II Diabetes Mellitus →

Sponsor

Getz Pharma — full company profile →

Who can join

Adults 18 to 75, any sex, with Type II Diabetes Mellitus. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To compare the safety and efficacy of empagliflozin versus other treatments in Pakistani Muslim population with type II diabetes mellitus.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Safety and efficacy of Empagliflozin in Pakistani Muslim patients with type 2 diabetes (SAFE-PAK); a randomized clinical trial.
Aamir AH, Raja UY, Qureshi FM, Asghar A, et al · · 2022 · cited 1× · PMID 36443769 · DOI 10.1186/s12902-022-01213-1
Safety and efficacy of Empagliflozin in Pakistani Muslim Patients with Type 2 Diabetes (SAFE-PAK); A Randomized Clinical Trial
Aamir AH, Raja UY, Qureshi FM, Asghar A, et al · · 2022 · DOI 10.21203/rs.3.rs-1798584/v1

Verify or expand the search:

Other trials of Empagliflozin

Trials testing the same drug.

NCT07060417 — Vascular Effects of SGLT2i in Non-diabetic CKD · Phase 2 · not yet recruiting
NCT06625073 — Randomized Trial of SGLT2i in Heart Transplant Recipients · Phase 4 · recruiting
NCT07107945 — A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease · Phase 3 · recruiting
NCT07214818 — SGLT2 Inhibitors in Adult Primary Nephrotic Syndrome · Phase 2, PHASE3 · active not recruiting
NCT07180745 — Empagliflozin Versus Statins in Non-Alcoholic Fatty Liver Disease · Phase 4 · not yet recruiting

Other recruiting trials for Type II Diabetes Mellitus

Currently open trials in the same condition.

NCT07495956 — cfMSC Therapy for Diabetes · Phase 1, PHASE2 · recruiting
NCT07340320 — A Study of CX11 Tablets in Patients With Type 2 Diabetes Mellitus · Phase 2 · recruiting
NCT06561126 — Engagement of coMmunity Through Participatory Learning and Action for cOntrol and preVEntion of Type II Diabetes and Its · NA · recruiting
NCT07350694 — Engagement of coMmunity Through Participatory Learning and Action for cOntrol and preVEntion of Type II Diabetes and Its · NA · recruiting
NCT06387550 — Effects of Eccentric Training on Glycemic Control and Quality of Life in Patients With Type II Diabetes Mellitus · NA · recruiting

Other Getz Pharma trials

Trials by the same sponsor.

NCT07174297 — Acotiamide vs Itopride in Postprandial Distress Syndrome · Phase 3 · not yet recruiting
NCT07031141 — Diabetes Foot Africa Region Registry · not yet recruiting
NCT06706609 — Classification of Adult-onset Diabetes in Five Subgroups in Pakistani Population · not yet recruiting
NCT05977647 — Medical Stone Expulsive Therapy for Acutely Obstructed Ureteric Calculi · Phase 4 · completed
NCT05644717 — Effect of Erugliflozin On Liver Fat, Liver Fibrosis and Glycemic Control in Type II DM Patients With NASH/NAFLD · Phase 4 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04665284 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Getz Pharma
Last refreshed: 11 December 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04665284.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing